◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

Home › All stocks › C › CORONA

CORONA Remedies Limited (CORONA) Financial History

4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

Healthcare · Drug Manufacturers - General · DATA UPDATED 2026-09-20

CORONA Remedies Limited (CORONA) operates in the Drug Manufacturers - General industry and is headquartered in Ahmedabad, India with about 5,153 employees. In the fiscal year ended 2026-03-31, CORONA reported ₹14.0B in revenue and ₹1.9B in net income.

CORONA Remedies Limited, a pharmaceutical formulation company, develops, manufactures, and markets pharmaceutical products. It provides products in women's healthcare, cardio-diabeto, pain management, urology, thyroid management, respiratory, nutraceuticals, gastroenterology, and other therapeutic areas.

Interactive charts & full statements →

CORONA Revenue & Earnings History — Annual Income Statement

Income statement	2026-03-31	2025-03-31	2024-03-31	2023-03-31
Total Revenue	₹14.0B	₹12.0B	₹10.1B	₹8.8B
Gross Profit	₹11.4B	₹9.6B	₹7.9B	₹6.7B
Operating Income (EBIT)	₹2.6B	₹2.0B	₹1.3B	₹1.1B
Net Income	₹1.9B	₹1.5B	₹905M	₹849M

INR; ₹M / ₹B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

CORONA Quarterly Revenue & Earnings — Last 8 Quarters

Quarterly income statement	2026-03-31	2025-12-31	2025-06-30	2025-03-31	2024-12-31
Total Revenue	₹3.5B	₹3.4B	₹3.5B	₹2.9B	₹3.0B
Gross Profit	₹2.9B	₹2.8B	₹2.8B	₹2.4B	₹2.4B
Operating Income (EBIT)	₹517M	₹737M	₹610M	₹442M	₹597M
Net Income	₹453M	₹413M	₹462M	₹316M	₹450M

INR; ₹M / ₹B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

CORONA Free Cash Flow History

Cash flow	2026-03-31	2025-03-31	2024-03-31	2023-03-31
Dividends Paid	(₹447M)	(₹226M)	(₹169M)	(₹70M)

INR; ₹M / ₹B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

CORONA Quarterly Free Cash Flow — Last 8 Quarters

Quarterly cash flow	2025-06-30
Dividends Paid	(₹408M)

INR; ₹M / ₹B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

CORONA Balance Sheet History

Balance sheet	2026-03-31	2025-03-31	2024-03-31	2023-03-31
Total Assets	₹12.1B	₹9.3B	₹8.3B	₹6.0B
Total Liabilities	₹4.6B	₹3.2B	₹3.5B	₹1.9B

INR; ₹M / ₹B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive CORONA viewer.

Other Companies in Drug Manufacturers - General

AMRN · Amarin Corporation plc — $288 million
SCLX · Scilex Holding Company — $37 million
MIRA · MIRA Pharmaceuticals, Inc. — $36 million
MDCX · Medicus Pharma Ltd. — $11 million
4519 · Chugai Pharmaceutical Co., Ltd. — JPY 11.10 trillion
4578 · Otsuka Holdings Co., Ltd. — JPY 5.83 trillion
4568 · Daiichi Sankyo Company, Limited — JPY 5.37 trillion
4503 · Astellas Pharma Inc. — JPY 4.27 trillion

← COROMANDEL All “C” companies CORP →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.